Systematic literature review of clinical outcomes, health-related quality of life, and healthcare costs and resource use in relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel

Lymphoma

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis

Lancet Haematol

Spanjaart AM, Bakker M, de Vries R, Hutten BA, van Nieuwenhuijzen N, Minnema MC, Kuipers MT, Kersten MJ

doi: 10.1016/S2352-3026(26)00045-1

Lymphoma

Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review

Leuk Lymphoma

Kim DH, Cha S, Koh Y, Byun JM

doi: 10.1080/10428194.2026.2638438

Lymphoma

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma

Blood

Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin IA, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu SS, Wagner-Johnston ND, Ollila TA, Grover NS, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov AV, Tun HW, Munoz J, Narkhede MS, Rhodes JM, Prica A, Kuhnl A, Maraj AM, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Firas FB, Monick S, Trutzer IM, Can J, Ayers AA, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K

doi: 10.1182/blood.2025031455

Lymphoma

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

Blood

Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning MA, Egini O, Odstrcil Bobillo MS, Kallam A, Kambhampati Thiruvengadam S, Lee D, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I

doi: 10.1182/blood.2025031733

Lymphoma

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma

Haematologica

Rocha V, Mooyaart JE, Ram R, Clesham K, Daskalakis M, Huynh A, Potter V, Chaganti S, Gabellier L, Tholouli E, Collin M, Nicholson E, Protheroe R, Passweg J, Ayuk F, Schneidawind D, Kwon M, Corral LL, Zeiser R, Scheid C, Yakoub-Agha I, Dreger P, Stolzel F, Hoogenboom J, Coelho MHM, Tomas AA, Malard F, Kuball J, Sureda A, Barzabachi A, Ruggeri A

doi: 10.3324/haematol.2026.300508

Lymphoma

A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma

Am J Hematol

Gugliotta G, Argnani L, Cantelli M, Pinto A, Gorgone A, Piazza F, Fozza C, Fesce VF, Marino F, Celli M, Pennese E, Gaudio F, Lauzzana P, Pezzullo L, Lorenzo S, Nierychlewska PM, Ceparano G, Pane F, Casadei B, Pellegrini C, Romano C, Zinzani PL

doi: 10.1002/ajh.70317

Lymphoma

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence

Blood Cancer J

Perrone S, Molica M, Giannarelli D, Pacitto G, Ferrero S

doi: 10.1038/s41408-026-01552-5

Lymphoma

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial

J Clin Oncol

Matasar M, Li Z, Vassilakopoulos TP, Sancho JM, Viardot A, McMillan A, Dal MS, Pereira J, Kim JS, Qiu L, Batlevi CL, Ibrahim R, Hernandez J, McCall B, Jiang Y, Yan M, Harris W, Musick L, Haioun C

doi: 10.1200/JCO-25-02849

Lymphoma

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial

J Clin Oncol

Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Cordeiro de Farias DL, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J

doi: 10.1200/JCO-25-01957

Related content

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis

Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma

A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial